Label Image (Lbl500904252)
Losartan Potassium
Product Images NDC 50090-4252
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 50090-4252). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Fig 2 (Losartanpotassiumfig2)
The given text seems to show a comparison of two medications, atenolol and losartan potassium, in terms of their effectiveness in reducing the risk of fatal/non-fatal stroke in patients. It also mentions an adjusted risk reduction of 25% with p-value of 0.001. The rest of the text appears to show a graph with study months on the x-axis and RAiTI values on the y-axis. It is not possible to determine the complete context or meaning of the given text.*
Fig 4 (Losartanpotassiumfig4)
The text appears to be a chart displaying data for a study comparing Losartan Potassium to a placebo in patients with an event. The chart shows the number of patients (60, 40, 20) and a risk reduction percentage of 16.1%, with a p-value of 0.022. However, without additional context or information, it is unclear what type of event is being studied or the significance of the results.*
Fig 1 (Losartanpotassiumfigure1)
The text seems to be a chart or a graph that displays the percentage of patients with the primary endpoint for two different medications, Atenolol and Osartan Potassium. It also shows an adjusted risk reduction of 13% with a p-value of 0.021. The timeline of the study goes up to 66 months.*
Fig 3 (Losartanpotassiumfigure3)
This appears to be a table or chart displaying results of a study involving patients divided into categories such as age, gender, race, and medical history. The study also involved comparing two medications, losartan potassium and atenolol, and reporting the number of events and hazard ratios associated with each. However, without more context or a clearer format, it is difficult to draw meaningful conclusions from this information.*
Losartan Potassium (Losartanpotassiumstrfrm1)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
